<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marjan Meurisse</style></author><author><style face="normal" font="default" size="100%">Adrien Lajot</style></author><author><style face="normal" font="default" size="100%">Yves Dupont</style></author><author><style face="normal" font="default" size="100%">Marie Lesenfants</style></author><author><style face="normal" font="default" size="100%">Sofieke Klamer</style></author><author><style face="normal" font="default" size="100%">Javiera Rebolledo</style></author><author><style face="normal" font="default" size="100%">Tinne Lernout</style></author><author><style face="normal" font="default" size="100%">Mathias Leroy</style></author><author><style face="normal" font="default" size="100%">Arnaud Capron</style></author><author><style face="normal" font="default" size="100%">Johan Van Bussel</style></author><author><style face="normal" font="default" size="100%">Sophie Quoilin</style></author><author><style face="normal" font="default" size="100%">Emmanuel André</style></author><author><style face="normal" font="default" size="100%">Kaat Kehoe</style></author><author><style face="normal" font="default" size="100%">Luc Waumans</style></author><author><style face="normal" font="default" size="100%">Van Acker, Jos</style></author><author><style face="normal" font="default" size="100%">Vandenberg, Olivier</style></author><author><style face="normal" font="default" size="100%">Van den Wijngaert, Sigi</style></author><author><style face="normal" font="default" size="100%">Ann Verdonck</style></author><author><style face="normal" font="default" size="100%">Lize Cuypers</style></author><author><style face="normal" font="default" size="100%">Dieter Van Cauteren</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">One year of laboratory-based COVID-19 surveillance system in Belgium: main indicators and performance of the laboratories (March 2020-21).</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Public Health</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium; COVID-19; Laboratory-based surveillance; SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Oct 27</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">79</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;With the spread of coronavirus disease 2019 (COVID-19), an existing national laboratory-based surveillance system was adapted to daily monitor the epidemiological situation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Belgium by following the number of confirmed SARS-CoV-2 infections, the number of performed tests and the positivity ratio. We present these main indicators of the surveillance over a one-year period as well as the impact of the performance of the laboratories, regarding speed of processing the samples and reporting results, for surveillance.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;We describe the evolution of test capacity, testing strategy and the data collection methods during the first year of the epidemic in Belgium.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Between the 1 of March 2020 and the 28 of February 2021, 9,487,470 tests and 773,078 COVID-19 laboratory confirmed cases were reported. Two epidemic waves occurred, with a peak in April and October 2020. The capacity and performance of the laboratories improved continuously during 2020 resulting in a high level performance. Since the end of November 2020 90 to 95% of the test results are reported at the latest the day after sampling was performed.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Thanks to the effort of all laboratories a performant exhaustive national laboratory-based surveillance system to monitor the epidemiological situation of SARS-CoV-2 was set up in Belgium in 2020. On top of expanding the number of laboratories performing diagnostics and significantly increasing the test capacity in Belgium, turnaround times between sampling and testing as well as reporting were optimized over the first year of this pandemic.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>